Anait Galfaian, MD
Family Medicine · Glendale, CANPI 1447358981
Payments from drug & device makers
Across 180 payments — averaging $48.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Novo Nordisk$1K
- Abbott$1K
- Amarin Pharma, Inc.$771
- Biohaven Pharmaceutical Holding Company Ltd.$507
- Johnson & Johnson$502
- plus $2K from 17 others
What the payments were for
- Travel & lodging$2283%
- Food & beverage$8,45497%
- Education$230%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 38 | $2,329 |
| Novo Nordisk | 39 | $1,322 |
| Abbott | 16 | $1,187 |
| Amarin Pharma, Inc. | 12 | $771 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $507 |
| Johnson & Johnson | 11 | $502 |
| GSK | 12 | $415 |
| AstraZeneca | 4 | $338 |
| Boehringer Ingelheim | 12 | $283 |
| AbbVie | 7 | $233 |
| Ironwood Pharmaceuticals, Inc | 7 | $222 |
| Optinose US, Inc. | 1 | $127 |
| Idorsia Pharmaceuticals US Inc | 1 | $125 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $100 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| Sumitomo Pharma America, Inc. | 1 | $30 |
| Biohaven Pharmaceuticals, Inc. | 1 | $26 |
| Medtronic | 1 | $25 |
| Sunovion Pharmaceuticals Inc. | 1 | $22 |
| Pfizer | 1 | $17 |
| Ardelyx, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$786
- EVENITY$664
- XARELTO$368
- Ozempic$368
- RYBELSUS$341
- NURTEC ODT$308
- Quadra Assura CRT Defibrillator$287
- Vascepa$254
- Prolia$242
- Confirm Rx$177
- Fortify Assura$132
- LINZESS$128
- Xhance$127
- QUVIVIQ$125
- Creon$121
- Otezla$120
- TRELEGY ELLIPTA$119
- AIRSUPRA$116
- Optisure Defibrillation ICD Lead$113
- FARXIGA$110
How this compares
$8,706 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Sodium | 1,358 | $604,316 |
| Icosapent Ethyl | 1,680 | $268,957 |
| CreonLipase/Protease/Amylase | 261 | $258,712 |
| LinzessLinaclotide | 404 | $213,574 |
| EliquisApixaban | 492 | $213,365 |
| VascepaIcosapent Ethyl | 735 | $207,870 |
| JardianceEmpagliflozin | 345 | $188,880 |
| Fluticasone-VilanterolFluticasone/Vilanterol | 451 | $157,548 |
| OzempicSemaglutide | 144 | $136,773 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 308 | $119,158 |
| ProliaDenosumab | 59 | $100,407 |
| JanumetSitagliptin Phos/Metformin Hcl | 178 | $94,326 |
| EntrestoSacubitril/Valsartan | 157 | $87,624 |
| Pitavastatin Calcium | 389 | $69,079 |
| Zileuton ErZileuton | 29 | $68,294 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess, Namzaric | $233 | $505,715724 claims |
| Boehringer IngelheimJardiance, Tradjenta, Jentadueto, Synjardy | $283 | $322,006611 claims |
| PfizerEliquis | $17 | $213,365492 claims |
| Novo NordiskOzempic | $1,322 | $136,773144 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $415 | $113,948244 claims |
| AmgenProlia | $2,329 | $100,40759 claims |
| Johnson & JohnsonXarelto | $502 | $51,06591 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $38 | $39,36485 claims |
| AstraZenecaFarxiga | $338 | $35,26061 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.
Other family medicine in Glendale
- Esther YoonGlendale$5.8M
- David HanGlendale$2.3M
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.